mpncancer

January 8, 2018
Celgene MPN drug Fedratinib

Celgene Acquires Impact Biomedicines, Adding Myeloproliferative Neoplasm Drug Fedratinib to Its Pipeline

Celgene Corporation (NASDAQ:CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for […]
December 27, 2017
Dr Mascarenhas presenting at ASH 2017 on Nutlin

ASH 2017 Nutlin Antagonist Shows Activity in Polycythemia Vera

The investigational Nutlin family antagonist idasanutlin demonstrated significant activity and was well tolerated after multiple cycles of exposure in patients with refractory polycythemia vera (PV). Data […]
December 1, 2017

What is an MPN Specialist?

One Simple Criteria If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never […]
June 29, 2017
Pegasys Jakafi combo for MPNs

Minimal Residual Disease or Cure in MPNs? Rationales and perspectives on Combo Therapy with Interferon-alpha2 and Ruxolitinib

This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of […]
June 15, 2017
Dr Ruben Mesa

Dr Ruben Mesa, MPN Specialist named new director of University Texas Health Care Cancer Center in San Antonio

UT (University of Texas) San Antonio makes Dr. Ruben Mesa head of their Cancer Center Dr Ruben Mesa, one of the leading MPN Specialist in the […]
January 29, 2017
ruxolitinib and pegasys for treating MPNs

Dr Mesa and Dr Mikhael Discuss Latest MPN Research 2017

A Solid Summary on the Latest MPN Research in 2017 Drs. Joseph R. Mikhael and Ruben A. Mesa analyze and discuss pertinent clinical studies and late […]
Do NOT follow this link or you will be banned from the site!
Malcare WordPress Security